Epithelial Ovarian Cancer – Pipeline Review, 2019

Ovarian cancer is one of the most common types of gynecology cancer. There are different types of epithelial ovarian cancers such as High-grade serous epithelial ovarian cancer, Mucinous, Low-grade serous, undifferentiated or unclassified, endometrioid, borderline tumors, Brenner tumors, and ovarian carcinosarcoma. According to the American Cancer Society, annually an estimated 239,000 new cases of ovarian cancer are diagnosed and ovarian cancer is responsible for 152,000 deaths worldwide each year.

Surgery, chemotherapy, and other medications are part of the current treatment of epithelial ovarian cancer. Surgery is often the first treatment of choice for epithelial ovarian cancer. Surgery is being used in combination with chemotherapy with paclitaxel plus carboplatin. A drug called bevacizumab is also used for the treatment of epithelial ovarian cancer.

At present, the majority of clinical trials are being performed by universities, and most candidates are in the early stages, with only a few candidates in the late stage. A clinical trial for defactinib (VS-6063), which is being conducted by Verastem, Inc., for safety, pharmacodynamics, pharmacokinetics, and preliminary clinical activity of defactinib in combination with avelumab in epithelial ovarian cancer is in Phase 1.

Currently, more than 80% of the pipeline candidates for Epithelial Ovarian Cancer are in phase-1 and phase-2. Majority of the studies have been sponsored by universities and academic research institutes. 

Report Description

The report on ‘Epithelial Ovarian Cancer – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Epithelial Ovarian Cancer. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Epithelial Ovarian Cancer.

The report on ‘Epithelial Ovarian Cancer – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases.

Reasons to Buy this Report 

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Epithelial Ovarian Cancer
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Epithelial Ovarian Cancer
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary